SCN8A seizure drug study halted early

NCT ID NCT04873869

Terminated Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 29 times

Summary

This study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare genetic epilepsy (SCN8A-DEE). The goal was to see if adding this drug to their current seizure medicines could reduce seizure frequency. The study was terminated early, so results are limited. Participants had to have at least one countable motor seizure per week and had already tried at least two other seizure drugs without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Children's National Hospital

Washington D.C., District of Columbia, 20010, United States
Cook Children's Medical Center

Fort Worth, Texas, 76104, United States
UCSF Medical Center

San Francisco, California, 94158, United States
University of Rochester

Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.

SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY SYNDROME